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The simultaneous effect of highly active anti-retroviral therapy (HAART) and nutritional supplements on 
cluster of differentiation4 (CD4)count of 100 people living with HIV/AIDS  (PLWHA) was investigated.  CD4 
cell count was determined using the Cyflow SL-3. Individuals with baseline CD4 counts less than 200 
cells/µl were placed on HAART for a period of 8 weeks at 4 weekly intervals. Total white blood cell 
(TWBC), haemoglobin (Hb)/ packed cell volume (PVC) were estimated using Sysmex KX-21N automated 
machine; Body mass index (BMI) calculated using World Health Organization’s BMI Reference Standards. 
Dietary intake and feeding history were recorded, followed by a 24 hourly dietary recall with 
Recommended Dietary Intake [RDA] of ELERON nutritional supplement. Eighty-one percent of treated 
subjects had increased CD4 count (P<0.05): TWBC had 24% increase; mean value (P<0.05).  Haemoglobin 
and PCV showed significant increase (P < 0.05) at 5% or 10% levels. Concomitant effect of HAART and 
nutritional supplements on the CD4 count, Hb/PCV, BMI were significant at 5% or 10% levels.  Mean BMI 
value was highly significant (20.23 kg/m2) compared with 16.40 kg/m
2
 (P=0.004). Immunological 
reconstitution of patients was observed following improved nutritional supplementation with HAART as 
effective adjunctive therapy/or clinical outcome-enhancer for PLWHA in rural and resource poor 
communities. 
 




Antiretroviral therapy (ART) reconstitutes the 
immune system and improves survival of the people 
living with HIV/AIDS.  Access to antiretroviral 
therapy (ART) is currently expanding in low and 
middle-income countries, especially the sub-
Saharan Africa, where it has become a cost-
effective public health intervention (Valdez et al., 
2001). Plasma viral load (VL) monitoring, the gold 
standard used in advanced countries for diagnosing 
virological failure, is not available in many under-
developed and developing countries due to the 
constraint of  infrastructure and high expense.  
WHO however, has recommended an alternative; 
the use ofCD4cellcount measurements and clinical 
outcomes for monitoring ART in the absence of viral 
load monitoring (WHO, 2006).  CD4, a  measure of 
CD4 cells in the blood, serves as a direct monitor of 
the progression of HIV as well as the response of 
the immune system to treatment with antiretroviral 
drugs (ARD) (Brooks 2007; Willey et al, 2008; 
Biron, 2010).   
Advanced HIV disease (AIDS), 
compromises the gastrointestinal tract (GIT) with 
severe infestation by several opportunistic parasitic 
pathogens (Cheesbrough, 2006), leading to 
imbalance in the micro and macro nutrients; with 
increased HIV progression to AIDS. Nutritional 
deficiencies chiefly vitamins and micronutrients 
(VMD) decrease epithelial integrity, weaken 
antibody responses and facilitate changes in the 
body’s normal flora (Willey et al., 2008; Thurnham, 
2010). Nutritional supplements in forms of 
haematinins (multivite, fesolate and folate), coupled 
with  balanced diet, fruits, vegetables and others, 
which contain the necessary micro and macro 
nutrients improve the nutritional status and hasten 
immune reconstitution of HIV infected persons. The 
nutritional status of the patients can be assessed 
using anthropometric methods such as body mass 
index (BMI) calculated from a person's weight and 
height as weight/height
2
. BMI , which correlates with 
direct measure of body fat such as underwater 
weighing and dual energy x-ray absorptiometry 
(DXA), is a fairly reliable indicator of body fatness 
for most people (FAO/WHO, 2006). The study 
evaluated the concomitant effect of antiretroviral 
therapy (art) and nutritional supplements on CD4 
count of people living with HIV/AIDS (PLWHA) in 
selected rural and resource limited communities of 
Nigeria, with the view to establish the immunologic, 
metabolic, and clinical effect or outcome in HIV-
infected patients taking highly active antiretroviral 
therapy (HAART). The micronutrient supplement 
may hold promise as an adjuvant therapy in the 
management of PLWHA. 
 
Materials and Methods 
 
Study population: The study population consisted 
of 280 individuals referred for HIV screening and 
counseling by physicians at the Enugu-Ezike 
District Hospital, a HIV Referral Centre designated 
for HIV voluntary testing and counseling (VTC) and 
for antiretroviral therapy and counseling for people 
living with HIV/AID in the area.  Participants were 
selected on the basis of their presenting clinical 
symptoms, including wasting syndrome, oral thrush, 
dermatological conditions. Out of the total number 
screened, one hundred (100) were HIV positive and 
these constituted the study population (picked on 





the basis of their HIV seropositive status). These 
were then subjected to regular visits and monitoring 
at their different homes from onset of study. All the  
subjects,  60.8% males, and 39.2% females, 
(median age, 38 years [range, 18-60 years]) who 
were naive to antiretroviral therapy, commenced the 
antiretroviral cum nutritional supplement treatment 
during the study period with intensive follow-up 
visits. Demographic characteristics of subjects 
including age, gender, occupation and education 
were obtained from questionnaire administration. 
The benefits, confidentiality and voluntary 
participation features of the study were explained 
and written informed consent obtained from the 
subjects followed by approval by the ethical 
committee of the various participating clinics and 
hospitals as well as the Research Ethics Committee 
of the University of Nigeria, according to the 
Declaration of Helsinki (World Medical Association 
and Council for International Organizations of 
Medical Sciences (CIOMS), prior to commencement 
of study.  Eligibility criteria were restricted to 
subjects between the age ranges of 19 to 60 years. 
 
HIV screening: A 5-ml sample of blood was 
collected from each patient by venipuncture into a 
Vacutainer EDTA bottle and screened for HIV-1 
antibodies using the Genie HIV-1/2 kit (Sanofi 
Diagnostics Pasteur, Montreal, Quebec), a 
synthetic-peptide solid-phase enzyme 
immunoassay according to Manufacturer’s 
instructions. The lower limit of detection of this 
assay was 400 copies per milliliter. 
 
CD4 cell count: HIV positive samples were 
assayed for CD4 by the Cyflow technique using the 
Cyflow counters (Partec, Germany), for both 
counting and analyses of particles and cells. Blood 
samples were stained with fluorescent dye, and 
allowed to stand for about 5 mins for the dye 
molecules to be imbibed by the cells (this was 
illuminated at defined wavelength). The color 
intensity for each labeled cell was measured by a 
ploidy analyzer; the intensity of emitted light was 
proportional to its CD4.  The concentration or 
volume of fluorescent cell was measured at 0.2 ml 
by the volume detector, while the ploidy analyzer 
determined the number of cells per ml. CD4 cell 
counts were monitored at 6 month intervals.  
Overall treatment efficacy was defined as an 
increase of the CD4 cell count by at least 50% of 
the baseline value, while AIDS was defined as 
clinical stage C of the 1993 classification system 
(CDC, 1993).  
 
Baseline characteristics: “Baseline” CD4 cell 
count was date of HAART initiation and the levels 
were nearest the HAART initiation within 6 months 
before HAART. BMI was calculated using height 
and weight values within 30 days to 1 year before 
HAART initiation.  No deaths were observed during 
the study period; only 5 dropouts were recorded 
before the commencement of the study, and these 
were among the 180 HIV seronegative cases that 
were not considered eligible for the study, hence, 
were excluded. 
 
Antiretroviral therapy: Highly active antiretroviral 
therapy (HAART), combination therapy was 
administered to subjects  following the World Health 
Organization (WHO) guideline, as follows:  
Zidovudine (AZT): 300 mg twice daily;  
Lamivudine (3TC): 150 mg twice daily;  
evirapine (NVP):  200 mg twice daily for first 14 
days;  
Efavirenz (EFV): 600 mg   once daily (at bedtime);  
Stavudine (D4T): 40 mg every 12 hours for adults of 
> 60kg and 30mg every 12 hours  for adults < 60kg;   
Didanosine (DdI): 400 mg once daily for adults > 
60kg and 250mg daily for adults < 60kg; Tenofovir 
(TDF): 300 mg once a day.   
Lopinavir (LPV): This was variable: adult dosing 
was dependent on formulation or treatment 
experience.  
 
Time was measured from the date of starting 
treatment to the date of the last follow-up visit (June 
2, 2009 to June 30, 2010). Patients were 
maintained in the original regimen for the period of 
study. Exclusion criterion included pregnant women 
as a result of difference in their HAART regimen 
requiring that women not already taking treatment, 
but requiring HAART, should defer commencement 
until second trimester after the period of 
organogenesis and when symptoms of morning 
sickness are likely to have settled.  Gestational 
period was not determined among the pregnant 
women, hence their illegibility for the study. Mega-
HAART, involving 3 or more antiretroviral drugs (for 
treatment failure) was avoided.  
 
Haematological tests: An automated Coulter 
counter T540 machine (Beckman/Coulter T540, 
USA), standardized against a 4C plus blood control 
was used for haematological parameter estimation.  
The machine automatically diluted 29.6 µl whole 
blood samples, lysed, counted and printed out the 
result of absolute numbers of White Blood Cells, 
Red Blood Cells and lymphocyte.  Potassium, 
Magnesium and Calcium, Urea, Creatinine and 
Albumin or Transferrin were however not measured. 
 
Investigation of anaemia in HIV/AIDS: As HIV 
infection has an effect on red blood cells, 
decreasing their lifespan and preventing their 
maturation and replacement by the bone marrow 
thereby engendering severe anaemia, haematologic 
indicators of HIV-associated anemia namely, iron 
deficiency or low haemoglobin content measured as 
HB and/or packed cell volume (PCV) and 
erythrocyte sedimentation rate (ESR) indicative of 
severity of infection were therefore investigated. 
Nutritional imbalance, another cause of HIV-
associated anaemia was similarly investigated. 
Other causes of anaemia such as opportunistic 
infections, vitamin B12 deficiency, autoimmune 
destruction of red blood cells as well as other 
causes of low or elevated white cell counts were 
however not determined. 
 
Selection for administration of nutritional 
supplement: Measurement of anaemia: The 
selection for nutritional supplement administration 
was, in addition to HIV status (seropositivity) based 
850 
Effect of Simultaneous Administration of Antiretroviral Therapy and Nutritional Supplements  
 
 
on evidence of malnutrition and associated 
anaemia, assessed by haemoglobin content or 
PCV, poor appetite, as well as physical examination 
for indicators of malnutrition such as the following: 
 
1. Weight loss (wasting syndrome) compared with 
body mass index  
2. Neurologic symptoms, including 
weakness/fatigue, gait abnormalities  pain and 
depression 
3. Mouth appearances such as angular stomatitis, 
papillar atrophy, cheilosis and other breakdown in 
oral mucosa 
4. Skin texture and appearance including  overt 
dryness, pealing, pallor, hyper or hypopigmentation 
 
Assessment of nutritional imbalance or 
malnutrition: Nutritional imbalance or malnutrition 
and related poor dietary intake from deficiency, food 
intolerance or aversion were assessed from dietary 
history during oral interviews.  Poor diet was 
reported as: 
1. Poor food choices, intolerance and allergies 
2. Skipping meals 
3. High sugar intake and high intake of refined 
foods, high alcohol consumption 
4. Low fruit and vegetable intake 
 
Anthropometric measurements for establishing 
relationship between body weight (weight loss) 
and HIV infection: Another index of nutritional 
status namely, anthropometric measurements of 
height and weight:  Body Mass Index (BMI), an 
indirect measurement of body composition, was 
used to assess level of weight loss (indicator of 
poor nutritional status, and typified by a low BMI) 
common in HIV infection. The values obtained from 
the BMI were compared to the World Health 
Organization’s Reference Standard for healthy 
individuals as follows: 
 Less than 18.5 underweight for individual  
height; 
 
 18.5 to 24.9, an ideal weight for individual  
height; 
 
 25 to 29.9, over the ideal weight for individual  
height; 
 
 30 and above, obesity (WHO, 2000).  
 
Body weights and heights were measured using a 
WEYLUX scale and a Stadiometer while observing 
standard precautions (RNIS, 2000). The BMI was 
calculated as: weight (kg) / [height (m)]
2 
 
Administration of nutritional supplements: 
Micronutrients: Micronutrients were provided in 
forms of fruits and vegetables. The diet plan or 
menu of the study population was fortified or 
supplemented with a cup of egg plant leaf (Solanum 
manocarpum) water or Ugwu, pumpkin (Telfairia 
occidentale) water three times daily in addition to 
filling half their plates with half cooked vegetable 
soup made from a variety of local vegetables  
including spinach, Vernonia amygdalina (onugbu or 
bitter leaf), ugwu, waterleaf, tomatoes, red pepper 
and any other African vegetable  available at each 
period.  Patients were in addition encouraged to 
have a variety of local fruits such as  oranges, 
guava, avocado pear, soursop pawpaw, mango, 
(Mangifera indica), watermelon, and other seasonal 
fruits as  much as possible during the day, and 
especially after meals as a  compulsory part of their 
diet plan.  Those in very bad condition (AIDS 
patients) with little or no appetite, were put on soft 
fruits such as avocado, banana, papaya or boiled 
vegetables such as carrot, or pumpkin. Compliance 
with additional intake of vegetables and fruits was 
achieved by follow up visits and regular counseling 
on the immense benefit of strict adherence to their 
diet plan for their survival.   
 
Administration of nutritional supplements: 
Nutritional supplements in form of ELERON 
Capsule [Iron (III) Hydroxide polymaltose Complex] 
containing elemental iron (100 mg), 550 mcg of folic 
acid and B-complex vitamin (Recommended Dietary 
Intake [RDI] of 2 tablets daily) were  administered to 
individuals with evidence of malnutrition and  
associated anaemia, indicated by both low BMI,  HB 
and/or PCV below normal ranges.Clinical symptoms 
of anaemia were established prior to medication 
from both the full blood count including the  
haemoglobin (HB) tests and the packed cell volume 
(PCV) from haematocrit measurement  according to 
the WHO’s threshold for the definition of anaemia 
(WHO, 2005).  Other clinical indicators or markers 
used included  shortness of breath(respiratory 
symptom), heart palpitation and arrhythmia (cardiac 
symptom), unsteady gait and postural stability, 
especially in the dark. 
 ELERON administration was based on 
WHO’S Hemoglobin thresholds for the definition of 
anaemia (1 g/dL = 0.6206 mmol/L),  in accordance 
with the daily recommended dose approved by 
National Agency for the Control of AIDS, Nigeria 
(NACA). Selection for the medication was as 
indicated earlier, on the basis of  seropositivity and 
other measures of anaemic condition. This regimen 
was fortified with increased intake of vegetables 
and fruits at each meal as indicated above.  Routine 
medications commonly used in Nigeria for PLWHA 
including Vitamin E, selenium and zinc were also 
administered on daily basis, though the effect of 
these micronutrients which were considered 
minimal was not monitored. 
 Efficacy of drug administration and 
nutritional supplementation was determined by 
comparison of the initial (baseline) and final CD4 
mean values, indicators of immune reconstitution or 
otherwise hence no control group was employed for 
the efficacy assessment. Overall compliance with 
medication was evaluated subjectively by oral 
interviews by investigators and medical personnel in 
attendance, and questions were on treatment and 
adherence.  Problems associated with medication 
and compliance were resolved during home 
visitations and follow-up exercises. 
 
Statistical analysis: All analyses were carried out 
on an intent-to-treat with basis. Continuous and 
categorical variables were analyzed using the 
Student t-test, Chi-square, one or two ways analysis 
of variance and regression models where 
appropriate. Available data were therefore grouped 
into dependable and undependable variables  
before application of the statistical tools.  Significant 
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differences level were put at 5% and not 10% as 
indicated. Repeated measures models were used to 
examine the concomitant impact of the treatment 
(HAART and nutritional supplementation) (Steel and 
Torrie, 1960). The primary end point of the study 
was to examine the effect of antiretroviral therapy 
and nutritional supplementation on immunologic 
parameters (CD4 cell count). 
 
Results and Discussion 
 
Result of a total of 100 subjects assigned to a 
combination HAART and nutritional regimen 
following baseline HIV and CD4 count are shown in 
Table 1. Most subjects showed evidence of a CD4+ 
T cell increase after HAART initiation. Significant 
increase in the mean CD4 cell count of patients was 
observed following drug combination therapy 
compared with baseline (P<0.05).    
 







% Mean  
Difference 
Total p-value 
AZT, 3TC, NVP 118.4286 183.2857 64.85714 54.76476 4.164 0.001 
D4T, 3TC,NVP 142.5000 230.2500 87.75000 61.57895 3.483 0.040 
ddI, TDF, LPV 123.7000 201.9000 78.20000 63.21746 3.503 0.007 
D4T, 3TC, NVP 93.1667 164.5000 71.33333 76.56526 2.235 0.076 
D4T, 3TC,EFV 146.6667 242.8333 96.16667 65.56817 4.246 0.008 
D4T, AZT, NVP 87.1667 180.5000 93.33333 107.0745 3.585 0.016 
AZT, 3TC, EFV 125.5000 225.0000 99.50000 79.28287 2.774 0.069 
 
AZT =  Zidovudine; 3TC = Lamivudine; NVP = Nevirapine; EFV = Efavirenz; d4T =  Stavudine; 
ddI = Didanosine; LPV = Lopinavir ; TDF = Tenofovir. The results were significant  at either 5% level. 
 
The D4T, 3TC, EFV combination was the highest in 
effectiveness, and markedly increased the CD4 
count of the subjects compared to the baseline 
(242.83cells/μl cf 146.67 cells/μl; P = 0.008). Next 
was the D4T, 3TC, NVP, with effective activity of 
230.25 cells/μl cf 142.50 cells/μl (P = 0.04); AZT, 
3TC, EFV and ddI, TDF, LPV, had activity of 225.00 
cells/μl  cf 125.50 cells/μl, (P = 0.007),  and 201.90 
cells/μl  cf 123.70 cells/μl (P = 0.007),  respectively. 
The combination of AZT, 3TC, NVP resulted in 
mean increase of CD4 count of the subjects (183.29 
cells/μl,  cf 118.43 cells/μl, P = 0.001) compared 
with the baseline, while  D4T, AZT, NVP had 
(180.50 cells/μl  cf 87.17 cells/μl, P = 0.016). The 
D4T, 3TC, NVP combination had mean increase of 




Fig. 2: Administration Profile:  Effect of different 
HAART drug combination on the CD4 count of the 
subjects 
 
AZT =  Zidovudine; 3TC = Lamivudine; NVP = Nevirapine; 
EFV = Efavirenz; d4T = Stavudine  ;  ddI = Didanosine; 
LPV = Lopinavir ; TDF = Tenofovir.; cf = compared with.  
The results were significant  at either 5% or 10% level. 
 
Effect of HAART on TWBC: On the effect of 
combination of different HAART on TWBC (Fig. 2),  
available results indicated  that ddI, TDF, LPV 
administration  had significant (P<0.05) increase on 
patients’ TWBC with  per cent increase of 24%. 
Furthermore, d4T, 3TC, NVP showed 21% 
increased on the TWBC at 5% significant level;    
D4T, 3TC, NVP had minimal  increase on  the 
TWBC (5%).  However, some drug combinations 
such as AZT, 3TC, NVP; D4T, 3TC, EFV; d4T, AZT, 
NVP and AZT, 3TC, EFV had no effect on subjects’ 
TWBC levels (P> 0.01); per cent mean differences 
were 0.00%, 13%, 14% and 5%, respectively.  
 
 
Fig. 2: Effect of combination of different HAART on 
TWBC 
 
AZT =  Zidovudine; 3TC = Lamivudine; NVP = Nevirapine; 
EFV = Efavirenz; d4T = Stavudine  ;  ddI = Didanosine; 
LPV = Lopinavir ; TDF = Tenofovir.; cf = compared with.  
The results were significant  at either 5% or 10% level. 
 
Effect of different HAART combination on 
haemoglobin levels: The activity of several 
HAART combinations on the haemoglobin level of 
subjects was significant (P< 0.05) (Fig. 3).  
However, no activity was observed in the 
administration of D4T, 3TC, EFV on the Hb of the 











Fig. 3: Effect of combination of different HAART on 
Haemoglobin levels 
 
AZT =  Zidovudine; 3TC = Lamivudine; NVP = Nevirapine; 
EFV = Efavirenz; d4T = Stavudine  ;  ddI = Didanosine; 
LPV = Lopinavir ; TDF = Tenofovir.; cf = compared with.  
The results were significant  at either 5% or 10% level. 
 
Effect on PCV: The  Effect of various combinations 
of used HAART on subjects PCV was variable:  
while AZT, 3TC, NVP; D4T, 3TC, NVP, DDI, TDF, 
LPV; D4T, 3TC, NVP and AZT, 3TC, EFV  
combinations exerted  significant increase on the 
PCV levels  (P<0.05); per cent mean differences, 
7%, 6%, 7%, 10% and 12%, respectively; no 
observable effect was shown by D4T, 3TC, EFV 




Fig. 4: Effect of different ART drug combinations on 
PCV  
 
AZT =  Zidovudine; 3TC = Lamivudine; NVP = Nevirapine; 
EFV = Efavirenz; d4T = Stavudine  ;  ddI = Didanosine; 
LPV = Lopinavir ; TDF = Tenofovir.; cf = compared with.  
The results were significant  at either 5% or 10% level. 
 
Effect of nutritional supplements: The efficacy of 
nutritional supplements on investigated parameters: 
CD4 count,  Hb, as well as the BMI  of subjects, 
was remarkable (Table 2). Concomitant 
administration of the various combinations of 
HAART and nutritional supplements (including 
increased intake of fruits and vegetables) had 
significant difference in the CD4 count, at 5% level 
of significance;  the mean Hb was  similarly  at 5% 
level of significance.   
 
Table 2: Concomitant effect HAART and 
nutritional supplements on the CD4 count, Hb 
































ART = Antiretroviral therapy; CD4 = Cluster of 
differentiation; Hb = Haemoglobin; BMI = Body Mass 
Index. The results above were significant at 5% level.  
 
Observed mean BMI value of HIV patients on 
antiretroviral medication and nutritional 
supplements was higher than those who were 
neither taking antiretroviral drugs nor nutritional 
supplements (20.23kg/m2 cf 16.40kg/m
2
, P = 
0.004). Negative correlation (- 0.17096) was 
however established between age and final CD4 
count (0.004332 cf 0.704519) following HAART 
administration and nutritional supplementation. Data 
on nutritional assessment of the HIV  positive 
subjects, giving details  of their BMI and weight 
evaluation at baseline, expressed as either an 
underweight, ideal weight, overweight or obese, 
based on their BMI (index of their nutritional status) 
indicated that  most of patients (72%) were 
underweight; 14% had ideal weight, 11%   were 
overweight  while  3% were obese (Fig. 2). 
Significant weight loss was therefore typified by low 
BMI in the absence of HAART and nutritional 
supplements. However, observed mean BMI value 
of HIV patients on antiretroviral medication  and 
nutritional supplements (ELERON Capsule 
supplemented with improved food intake of 
vegetables and fruits) was  higher than those who 






P = 0.004). Negative correlation (- 0.17096) was 
nevertheless found between age and final CD4 
count (0.004332 cf 0.704519) following HAART 










UW  =Underweight;  IW = Ideal weight 
OW = Overweight;       O = Overweight 
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The present study aimed at investigating the 
concomitant effects of antiretroviral therapy cum 
nutritional supplementation on CD4 cell count of 
immunocompromised, but treatment naïve 
individuals.  Significant changes in average CD4 
percent and in the rate of change of CD4 were 
observed among 81% of subjects   following 
HAART administration.  Our results confirm the 
beneficial effects of HAART in increasing CD4 
levels, and are in consonance with several 
evidence-based reports on the efficacy of HAART in 
CD4 increase and subsequent viral load reduction. 
Increase in CD4 cell count reflects reconstitution of 
the immune system, and this delays development of 
opportunistic infections (WHO, 2006). An abrupt 
decline in CD4 after acute HIV infection followed by 
a  rise, and subsequent return to normal range  
(close to pre-infection baseline)  after recovery from 
acute infection:  a biphasic increase in CD4; 50-120 
in first 3 months, was attributable to redistribution of 
memory CD4 cells from lymphoid tissue, followed 
by average increase of 2-7 cells/m
3
 through an  
expansion of naive CD4 cell population; viral 
enzyme functions were reported to be inhibited, 
their number reduced, with resultant  increase in 
CD4 cell as compared to initial number  (baseline) 
before the administration of ART (Joel and 
Hoffmann, 2011). 
In a study in a Swiss cohort reduced 
disease progression and mortality with HAART was 
reported; an average increase of more than 100 
CD4 cells/m
3 
were observed in patients who 
received triple or quadruple therapy continuously 
and who were also the most immune suppressed 
prior to HAART (Egger et al.,  1997).The  present 
study similarly observed the efficacy of HAART, a 
combination therapy with different classes of 
antiretroviral drugs; this phenomenon has been 
attributed to its unique mechanism of action, which 
is  mostly by blocking the action of enzymes that 
are important in replication and functioning of HIV. 
Observations from the present study 
therefore, establishes the efficacy of HAART in 
immune system restoration and consequently, 
boosting of CD4 cells. This view is supported by the 
reports indicating that by targeting multiple steps in 
HIV replication, HAART successfully turns HIV 
infection into a chronic treatable disease unlike 
mono-therapy which results in the rapid emergence 
of drug resistant mutants of HIV (Brooks et al., 
2007). Results of this study are also in consonance 
with several HAART therapeutic trials which have 
provided strong evidence that highly active 
antiretroviral combination therapy is effective at 
halting immunologic and clinical progression of HIV; 
achieving a reduction in viral loads, an increase in 
CD4 cell counts.  
Result of the effectiveness of HAART 
combinations on CD4 count was further expressed 
in their mean percentage values.  By evaluation, 
some drugs exerted higher activity on CD4 cells by 
achieving more increase in mean values of the CD4 
count compared to the baseline. Available result 
underscores the fact that CD4 expressed as a 
mean percentage is a better prognostic marker than 
the absolute CD4 counts, since it is  not affected by 
changes in total and differential leucocyte counts 
(not estimated in the study) as compared to the 
absolute counts in dual-platform technology  as  
earlier reported (Amatya, 2004). The use of CD4 
cell count in monitoring of rate of 
immunosuppression as well as indicator of ART 
effectiveness is herein established. The observed 
increase in mean CD4 count is an indication of 
HAART efficacy, and establishes a direct 
relationship between HAART administration and 
subsequent increase in mean CD4 cell. This view is 
supported by previous studies indicating that CD4, 
a measure of CD4 cells in the blood, serves as a 
direct monitor of the response of the immune 
system to treatment with antiretroviral drugs (ARD) 
as well as the progression of HIV (Brooks et al., 
2007; Willey et al., 2008; Biron, 2010). Though the 
cut-off values for CD 4 counts reported in the 
present study were not deduced from ROC curves 
(ROC curve Acronym for receiver operating 
characteristic curve; a graphical method of 
assessing the characteristic of a diagnostic test) 
previously determined for the estimation of CD4 
(DeLong et al., 1988). A large individual variability in 
CD4 measurement, a reflection of the method of 
determining CD4 count by calculation from 3 
measured variables: WBC, % lymphocytes, and % 
lymphocytes that are CD4+ (CD4%) was reported 
(Joel and Hoffmann, 2011). 
Result of this study observed low CD4 cell 
in spite of HAART regimen among some subjects.  
This could be related to several factors including 
individual immunologic or genetic factors, lack of 
adherence to drugs, decreased activity or failure of 
the thymus which functions in the maturation of 
CD4 cells to lack of compliance which results in 
drug resistance.  Similar resistance paradigm in 
their AIDS adherence training report in which 
adherence, which is the response (dose and time of 
intake) of an individual to drugs, was considered the 
most important factor in the success of ART was 
reported; resistance was hence attributed to lack of 
adherence to drug regimen  and high rate of viral 
replication. For ART to be effective, there should be 
greater than 95% adherence (WHO, 2006). 
The observed trend in theTWBC values in 
the present study is remarkable. Some ARD 
combinations, ddI, TDF, LPV; d4T, 3TC, NVP and 
D4T, 3TC, NVP markedly increased the TWBC 
values (P< 0.05) while others did not. The reported 
positive response (significant increase in TWBC) 
following the combination therapy was 
demonstrated in an  earlier study, which  attributed 
the apparent increase to the subjects’ innate 
immune responses, disease conditions and/or 
effects of nutritional supplements or both (Raxit, 
1995;Chandra, 1999).    On the other hand, the 
observed non response to ARD correlates  with the 
report  which showed that TWBC could be used to 
investigate infections and monitor treatments and 
that many infections can lead to disorders of the 
white blood cells which can be an increase in 
leucocytes numbers (leucocytosis)  in response to 
parasitic, bacterial or viral infections or absolute 
decrease in leucocyte numbers (leucopenia) 
caused by infections especially HIV (Cheesbrough, 
2006).The  argument was that since TWBC is the 
main component of the immune system, any 
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alteration in its values will therefore adversely affect 
the patient’s immune responses. Such incidence of 
low response was also alluded to cytotoxic drugs, 
drug reaction, folate and vitamin B12 deficiencies 
(Delves et al., 2006; UNAIDS/WHO/UNICEF, 2008), 
The complications of HIV infections are 
due to the interplay of malnutrition, mal-absorption, 
metabolic alteration and nutrients depletion 
associated with the HIV infection.  These nutrients 
are many including Zn, Se, Cu, Mn, sulphated 
amino acids (Thios) (Rice et al., 1995). 
Development of HIV-related opportunistic infections 
and malignancies which lead to decreases in CD4 
count also results in reduction in food intake 
resulting from reduced appetite or taste 
disturbances or painful mucosal lesion of the mouth, 
pharynx or oesophagus (Smith et al., 1992).  The 
efficacy of concomitant administration of HAART 
and nutritional supplement in increasing CD4 cell 
count and consequently reducing rate of HIV 
progression to active disease, AIDS, has been 
emphasized in this study: CD4 cell count, TWBC, 
HB, PCV and BMI of the people living with 
HIV/AIDS were significantly increased compared to 
the baseline values, thus buttressing the importance 
of nutritional supplement in the management of 
HIV/AIDS infections.  This opinion is in agreement 
with the FAO/WHO recommendation of 
micronutrients for PLWHA which is 10 – 20% above 
RDA (FAO/WHO, 2010; Thurnham, 2010). In a 
similar report, a correlation between nutrient 
supplementation and CD4 increase was further 
established; showing that low serum B12 is a 
predictor of disease progression, and those with low 
serum concentrations of retinol, B12  and zinc had 
significant decreases in CD4 count while those that 
developed normal serum levels of these 
micronutrients had an appreciable increase in CD4 
counts (Thurnham, 2010).  Studies have similarly 
shown that PLWHA are associated with low serum 
concentrations of Vitamin A, B6 , B12, C, E, folate,  
carotenoids as well as Se, Zn, and Mg (Lacy et al., 
1996 ).  The Na/K ratios and other biomarkers of 
inflammation for example, anaemia of chronic 
inflammation (ACI) with Hb values in the range of 
9.3–9.5g/l where haemoglobin and red blood 
synthesis is markedly depressed can inhibit iron 
absorption and re-utilization (Chandra, 1999).  
Available results further corroborates with the 
reports on the micronutrient supplementation and 
subsequent increase of CD4 count in HIV-infected 
individuals on HAART (Semba, 1997).  
The present study succinctly establishes 
the fact that increasing dietary supplementation of 
nutrients in form of ELERON Capsule (Iron (III) 
hydroxide polymaltose Complex) containing 
elemental iron 100mg and 550mcg of folic acid and 
B-Complex vitamin (RDI of 2 tablets daily) in 
conjunction with recommended doses of HAART  
markedly improved the health conditions of the 
HIV+ patients by increasing the CD4 counts 
compared with the baseline thereby delaying the 
progression of HIV to AIDS. This view finds 
credence  in the  randomized controlled trial (RCT) 
of HIV infected persons was  reported in which  a 
daily supplement of 800 IU vitamin  E and 1000 mg 
of vitamin C  given over three months period greatly 
reduced oxidative stress and was associated with 
appreciable increases in CD4 counts compared to 
the placebo (Allard et al., 1997). Failure of response 
to HAART and nutritional supplement by some 
subjects was however observed from this study. 
The nutrient-nutrient and nutrient-drug interactions 
is patient’s specific and could account for the 
minimal or non-response of some subjects to ART 
drug administration as observed in the present 
study, for example the abnormal Na/K and Ca/P 
ratios of subjects can affect the absorption and re-
utilization of these minerals due to imbalance in the 
body homeostasis (Dimtry et al., 2010).  
Furthermore, HAART treatment failure has 
been described as an emerging global challenge, 
especially in developing countries where HIV 
infection is still endemic and the use of HAART is 
being scaled up (Hawkins and Murphy, 2009). 
Nevertheless, results of the present study confirm 
the beneficial effects of combination therapy and 
nutritional supplementation despite the minimal 
compliance and adherence rates, which could 
further be attributed to either non-compliance to 
drugs, immune composition of the patient involved 
or the genetic makeup of the individual. The 
preferential effect of the concomitant administration 
of HAART and nutritional supplement in 
immunological reconstitution of HIV infection, is 
apparent from the study, which further reports that 
provision of  nutritional  supplements can be an 
easy and cost effective adjunctive therapy to boost 
immune status  of HIV infected persons,  decrease 
the side effects of HIV drug regimen and  enhance 
clinical outcomes among the PLWHA in rural 
communities facing the difficult ties of poor living 
standards. 
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